Every trial and approval built around a cancer biomarker.
23 biomarkers, matched against every interventional cancer trial on ClinicalTrials.gov and every FDA and EU approval we track. Updated 27 October 2026.
- Researchers and clinicians see every biomarker-selected trial, with the words that matched, and the pivotal results and side effects behind each approval. Try KRAS G12C
- Investors and analysts see where development is crowded or missing, who is running it, and what reads out next. Open the landscape
- Founders see the competition for a target, the companies behind it, and how far the EU lags the US. Browse companies
Biomarkers
| Biomarker | Active trials | Recruiting | FDA approvals | EU approvals |
|---|---|---|---|---|
| Mutations | ||||
| EGFR exon 19 deletion / L858RNSCLC | 399 | 189 | 16 | 13 |
| KRAS G12CNSCLC, colorectal, pancreatic | 254 | 145 | 4 | 2 |
| KRAS G12D Newpancreatic, colorectal, NSCLC | 207 | 128 | 0 | 0 |
| BRAF V600Emelanoma, colorectal, NSCLC, thyroid, tumor-agnostic | 164 | 87 | 17 | 13 |
| IDH1/2 mutation NewAML, glioma, cholangiocarcinoma, MDS, chondrosarcoma | 149 | 80 | 8 | 3 |
| BRCA1/2 mutationbreast, ovarian, prostate, pancreatic | 133 | 69 | 16 | 9 |
| FLT3 mutation (ITD/TKD) NewAML | 61 | 37 | 3 | 3 |
| PIK3CA activating mutation NewHR+ breast | 60 | 28 | 3 | 3 |
| EGFR exon 20 insertion NewNSCLC | 53 | 20 | 3 | 2 |
| NPM1 mutation NewAML | 51 | 39 | 2 | 0 |
| HER2 (ERBB2) activating mutation NewNSCLC | 49 | 26 | 5 | 1 |
| MET exon 14 skipping NewNSCLC | 33 | 17 | 2 | 2 |
| FGFR3 alteration (mutation or fusion) Newurothelial | 30 | 13 | 1 | 1 |
| ESR1 mutation NewHR+ breast | 9 | 7 | 5 | 2 |
| Fusions | ||||
| ALK fusionNSCLC, ALCL, IMT | 132 | 61 | 9 | 13 |
| ROS1 fusionNSCLC | 51 | 28 | 5 | 3 |
| RET fusion or mutation NewNSCLC, thyroid (incl. medullary), tumor-agnostic | 42 | 20 | 5 | 4 |
| FGFR2 fusion or rearrangement Newcholangiocarcinoma | 37 | 17 | 3 | 2 |
| NTRK1/2/3 fusiontumor-agnostic | 30 | 22 | 3 | 3 |
| NRG1 fusion NewNSCLC, pancreatic | 6 | 3 | 3 | 0 |
| Protein expression | ||||
| HER2-low / ultralow (IHC 1+ or 2+/ISH-)breast | 115 | 68 | 2 | 2 |
| Claudin 18.2 expression Newgastric/GEJ, pancreatic | 106 | 64 | 1 | 1 |
| Genomic signatures | ||||
| MSI-H / dMMRcolorectal, endometrial, tumor-agnostic | 223 | 98 | 16 | 9 |
Counts include trials that ask for a broader group containing the biomarker, such as "sensitizing EGFR mutation". Approvals count each approved indication separately. Pages marked New were added in v3.0 and have had fewer accuracy checks than the others.